Medpace Holdings Inc vs D Wave Quantum Inc — how do they compare? Medpace Holdings Inc trades at $532.89 (market cap $15.08B), while D Wave Quantum Inc trades at $17.84 (market cap $6.19B). The key difference: Medpace Holdings Inc is far larger — about 2.4× D Wave Quantum Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | QBTS | |
|---|---|---|
Market Cap | $15.08B | $6.19B |
Sector | Technology | Technology |
52-Week High | $620.59 | $44.78 |
52-Week Low | $308.88 | $12.98 |
Enterprise Value | $14.55B | $5.65B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
D-Wave Quantum (QBTS) trades at $16.73 with no change on the day, showing bearish technical signals despite a 100% analyst buy rating and $39.86 consensus price target. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains deeply negative profitability metrics with a -2,957.23% net income margin. Recent news highlights CEO share sales and sector volatility, while the stock's 29% July decline reflects investor concerns about execution risks in the emerging quantum computing space.
QBTS offers substantial upside potential based on analyst targets but carries high risk due to significant losses, negative cash flow from operations, and speculative technology timeline. The dual-platform quantum strategy provides competitive differentiation, but investors face volatility from pre-commercialization phase challenges and dependence on future funding rounds to sustain operations.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →